Dry Eye Rescue Is Offering Friends Of MDA A 20% Discount On All Products To Help With Your Eye Conditions

Click Here To Save Now

Jul 8, 2025

Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD

Author(s): Martin David Harp

Key Takeaways

  • Alcon’s acquisition of LumiThera includes a PBM device for early and intermediate dry AMD, enhancing its non-invasive treatment portfolio.
  • LumiThera’s PBM device demonstrated significant vision improvement in clinical trials, with no serious adverse events reported.
  • The acquisition excludes AdaptDx and Nova/Diopsys diagnostic devices, which will be spun off to LumiThera’s shareholders.
  • Alcon’s recent acquisitions, including Aurion Biotech and LENSAR, reflect its strategic expansion in eye disease treatments.

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living with early to intermediate dry AMD.

Earlier this year, Alcon announced it acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases, and intends to acquire LENSAR, including the ALLY Robotic Cataract Laser Treatment System, LENSAR’s proprietary Streamline software technology, and the LENSAR legacy laser system. Both deals are expected to close in mid-to-late 2025.

Sean Clark, vice president and general manager of the global surgical franchise at Alcon, commented on the planned acquisition of LumiThera in a press release from the company.

Read more: https://shorturl.at/oAKh2

Source: Ophthalmology Times

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.